Literature DB >> 10416833

Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue.

C Iehlé1, F Radvanyi, S Gil Diez de Medina, L H Ouafik, H Gérard, D Chopin, J P Raynaud, P M Martin.   

Abstract

We studied the expression level and cell-specific expression patterns of 5alpha-reductase (5alpha-R) types 1 and 2 iso-enzymes in human hyperplastic and malignant prostate tissue by semi-quantitative RT-PCR and in situ hybridisation analyses. In situ hybridisation established that 5alpha-R1 mRNA is preferentially expressed by epithelial cells and little expressed by stromal cells whereas 5alpha-R2 mRNA is expressed by both epithelium and stroma. Semi-quantitative RT-PCR has been performed on total RNA from different zones of normal prostate, BPH tissues and liver. We found that 5alpha-R1 and 5alpha-R2 mRNAs expression was near the same in all zones of normal prostate. In BPH tissue, 5alpha-R1 and 5alpha-R2 mRNAs expression was slightly but significantly increased, when it was compared to the levels recorded for normal prostate. In cancer samples, 5alpha-R1 mRNA expression was higher than in normal and hyperplastic prostate but the level of 5alpha-R2 mRNA was not statistically different from that observed in the different zones of normal prostate. In liver, 5alpha-R2 mRNA level was similar to that measured in BPH but 5alpha-R1 mRNA expression was ten times higher. The increase observed in 5alpha-R isoenzymes expression in BPH tissue could play an important role in the pathogenesis and/or maintenance of the disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10416833     DOI: 10.1016/s0960-0760(99)00030-8

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  26 in total

1.  Expression in Escherichia Coli, Purification, and Functional Reconstitution of Human Steroid 5α-Reductases.

Authors:  Hwei-Ming Peng; Juan Valentín-Goyco; Sang-Choul Im; Bing Han; Jiayan Liu; Jie Qiao; Richard J Auchus
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

2.  Molecular Basis of Steroid Action in the Prostate.

Authors:  Yuan-Shan Zhu
Journal:  Cellscience       Date:  2005-04-28

Review 3.  Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia.

Authors:  Chris Olesovsky; Anil Kapoor
Journal:  Ther Adv Urol       Date:  2016-05-26

4.  Effects of metoclopramide on mRNA levels of steroid 5α-reductase isozymes in prostate of adult rats.

Authors:  Pilar Sánchez; Jesús M Torres; Beatriz Castro; José F Frías; Esperanza Ortega
Journal:  J Physiol Biochem       Date:  2012-07-18       Impact factor: 4.158

Review 5.  Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function.

Authors:  Charles Welliver; Michael Butcher; Yogitha Potini; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2014-10       Impact factor: 3.092

Review 6.  Estrogen and androgen signaling in the pathogenesis of BPH.

Authors:  Clement K M Ho; Fouad K Habib
Journal:  Nat Rev Urol       Date:  2011-01       Impact factor: 14.432

Review 7.  Targeting 5α-reductase for prostate cancer prevention and treatment.

Authors:  Lucas P Nacusi; Donald J Tindall
Journal:  Nat Rev Urol       Date:  2011-05-31       Impact factor: 14.432

8.  5alpha-reductase: history and clinical importance.

Authors:  Leonard S Marks
Journal:  Rev Urol       Date:  2004

Review 9.  The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.

Authors:  Donald J Tindall; Roger S Rittmaster
Journal:  J Urol       Date:  2008-02-20       Impact factor: 7.450

10.  Semiquantitative RT-PCR method coupled to capillary electrophoresis to study 5alpha-reductase mRNA isozymes in rat ventral prostate in different androgen status.

Authors:  Jesus M Torres; José A Gómez-Capilla; Estrella Ruiz; Esperanza Ortega
Journal:  Mol Cell Biochem       Date:  2003-08       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.